StockData
Revvity, Inc. logo

Revvity, Inc. (RVTY) company profile

RVTYNYSELaboratory Analytical InstrumentsFiscal year ends December 29
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jul 5, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3042% above fair value
$147.79−1.06 (-0.71%)

Close on Nov 17, 2026Market cap $16.49BP/E 70.4Yield 0.19%

About Revvity

Laboratory Analytical Instruments, SIC 3826

Revvity provides health science technologies, expertise, and integrated workflow solutions bridging research, clinical discovery, and medical care. The company operates across two core segments: Life Sciences and Diagnostics. Its Life Sciences division delivers reagents, automated liquid handlers, imaging instruments, detection platforms, and research informatics designed to optimize drug development, genomics, and cellular analysis. Its Diagnostics segment supplies analytical instruments, diagnostic assays, screening kits, and laboratory data management software specializing in prenatal and newborn screening, immunodiagnostics, and infectious disease detection. Revvity serves pharmaceutical and biotechnology corporations, contract research organizations, academic and governmental research institutions, hospitals, clinical laboratories, and healthcare professionals.

Headquartered in Waltham, Massachusetts, the company conducts its commercial operations globally, marketing products and services across more than 160 countries. Its operational infrastructure includes a worldwide network of specialized genomic testing laboratories located in the United States, China, the United Kingdom, and India. Revvity maintains an international workforce of approximately 11,000 employees supporting its healthcare and diagnostic capabilities.

Summary of the business section of Revvity's latest annual report, written by StockData.

Company profile

Company

Legal name
Revvity, Inc.
Founded
1937
Headquarters
Waltham, MA
Address
77 4th Avenue 02451
Phone
(781) 663-6900
Employees
11,000, Dec 28, 2025
Industry
Laboratory Analytical Instruments
Incorporated in
Massachusetts
Fiscal year ends
December 29
Auditor
DELOITTE & TOUCHE LLP, Boston, Massachusetts

Stock & identifiers

Ticker
RVTY
Former tickers
PKI until Aug 1, 2023
Exchange
NYSE
Shares outstanding
112M, Aug 6, 2026
Public float
$11.30B, Jun 28, 2024
Filer category
Large accelerated filer
Stock splits
2-for-1, Jun 4, 2001; 2-for-1, May 11, 1992; 2-for-1, Feb 2, 1982; 2-for-1, Feb 4, 1980
SEC CIK
31791
CUSIP
714046109
ISIN
US7140461093
FIGI
BBG000FXW512
Share class FIGI
BBG001SBKS35
LEI
549300IKL1SDPFI7N655
EIN
04-2052042

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Prahlad R. SinghPlease See Remarks, Director159,895
Anita GonzalesVP and CAO7,117
Maxwell KrakowiakPlease See Remarks14,781
Tajinder S. VohraPlease See Remarks18,818
Joel S. GoldbergPlease See Remarks105,223
Miriame VictorPlease See Remarks18,122
Alexis P. MichasDirector71,265
Michael A. KlobucharDirector6,103
Michelle McMurry-HeathDirector5,248
Samuel R. ChapinDirector22,676
Peter BarrettDirector28,293
Sophie V. VandebroekDirector6,103
Frank WitneyDirector22,089
Michel VounatsosDirector12,712
Pascale WitzDirector14,720

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$13.81M$5.80M$3.94M$68$105
FY2024$11.93M$11.46M$2.85M$79$100
FY2023$9.13M$3.65M$2.22M$77$104
FY2022$10.58M$1.81M$2.07M$98$107
FY2021$9.66M$22.36M$2.40M$140$139
FY2020$9.02M$17.61M$2.95M$148$132

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Prahlad R. Singh
Chief Executive Officer
$1.13M$7.69M$2.56M$2.39M$40.73K$13.81M+16%
Maxwell Krakowiak
Senior Vice President and Chief Financial Officer
$550.58K$2.10M$2.10M$598.92K$27.62K$5.37M+66%
Joel S. Goldberg
Senior Vice President, Administration, General Counsel and Secretary
$564.62K$1.82M$604.24K$636.12K$46.64K$3.67M+8%
Miriame Victor
Senior Vice President and Chief Commercial Officer
$503.27K$1.53M$1.53M$509.08K$26.74K$4.10M+65%
Tajinder S. Vohra
Senior Vice President, Global Operations
$489.62K$1.21M$401.28K$515.59K$26.23K$2.64M+14%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 28, 2025, we employed approximately 11,000 employees on a worldwide basis.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 20, 2026DelistingNotice of delisting from exchange (Form 25)
Apr 14, 2023Name changeName changed from PERKINELMER INC to Revvity, Inc.
Mar 16, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 4, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 21, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 9, 2021DelistingNotice of delisting from exchange (Form 25)
Apr 11, 2018ListingRegistration of securities on an exchange (Form 8-A)
Feb 28, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 20, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 19, 2016ListingRegistration of securities on an exchange (Form 8-A)
Jan 19, 2012Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 7, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 3, 2010Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 20, 2007Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 12, 2007Tender offerThird-party tender offer for the company's shares
Dec 12, 2005Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 7, 2003MergerRegistration of securities for a merger or exchange offer (S-4)
Aug 3, 2001MergerRegistration of securities for a merger or exchange offer (S-4)
Nov 23, 1999MergerRegistration of securities for a merger or exchange offer (S-4)
Jul 26, 1999Name changeName changed from EG&G INC to PERKINELMER INC
Feb 9, 1995ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?